Calciprat Vitamine D3

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Calciprat Vitamine D3

Calciprat Vitamine D3 is a prescription-only (Rx) combined mineral and vitamin supplement that provides a dual formulation of essential nutrients. It is often prescribed to address or prevent deficiencies in both calcium and Vitamin D, which are critical for maintaining healthy bone density and function. This medicine is primarily manufactured by Alfasigma France.


Quick Facts Description
Active Ingredients Calcium Carbonate, Cholecalciferol (Vitamin D3)
Form Chewable tablet (often mint-flavored)
Pharmacological Class Mineral supplement and Vitamin D analog combination
Common Use Treating/preventing calcium and Vitamin D deficiency in high-risk groups

Therapeutic Use and Composition

This medication belongs to the pharmacological class of Calcium in combination with other substances, specifically Vitamin D. Its therapeutic use is broadly recognized in clinical settings, particularly as a core treatment for combined calcium and Vitamin D deficiencies in the elderly and as an adjunct treatment for osteoporosis (bone thinning) where insufficient intake of these nutrients is contributing to bone loss.

The formulation is fundamental to its efficacy. Calcium carbonate provides the essential mineral needed for bone structure, while Cholecalciferol (Vitamin D3) is included because it significantly enhances the body's natural processes for absorbing calcium from the gastrointestinal tract. This dual-action approach ensures that the body not only receives the necessary calcium but can also utilize it effectively to maintain bone strength and support normal muscle and nerve function.

Advertisements

What side effects are possible with Calciprat Vitamine D3?

Possible Side Effects and Safety Information

The safety profile for this combination of Calcium Carbonate and Cholecalciferol (Vitamin D3), as established in regulatory documents, is defined primarily by effects related to calcium metabolism and the digestive system.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by their expected frequency, based on official regulatory data:

  • Uncommon: These reactions include Hypercalcemia (elevated calcium levels in the blood) and Hypercalciuria (elevated calcium excretion in the urine).
  • Rare: Gastrointestinal disturbances such as constipation, flatulence, nausea, abdominal pain, and diarrhea are listed in this category.
  • Very Rare: Skin reactions like pruritus (itching), rash, and urticaria (hives) may occur.

Safety Considerations and Restrictions

Side effects are officially mapped to System-Organ Classes, primarily Metabolism and Nutrition Disorders and Gastrointestinal Disorders.

  • Dose and Duration: The risk of Hypercalcemia and Hypercalciuria is explicitly associated with prolonged treatment or administration at higher doses. Sustained Hypercalcemia can potentially lead to serious renal outcomes, such as nephrocalcinosis (kidney calcification) or irreversible renal impairment.
  • Population Specificity: Patients with renal impairment or chronic renal failure are noted in regulatory information as being at higher risk, necessitating close medical monitoring.
  • Restrictions: This product is restricted from use in individuals with pre-existing high calcium levels (Hypercalcemia or Hypercalciuria), Nephrolithiasis (kidney stones), or severe renal failure. Regular monitoring of serum and urinary calcium levels is recommended during long-term use.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Calciprat Vitamine D3 (Calcium Carbonate and Cholecalciferol) overdose centers on the development of Hypercalcemia (excess calcium in the blood) and Hypervitaminosis D (Vitamin D toxicity).


Documented Overdose Manifestations and Outcomes

Classification Manifestation/Outcome
Expected Manifestations Nausea, vomiting, decreased appetite (anorexia), frequent urination (polyuria), excessive thirst (polydipsia), fatigue, muscle weakness, and confusion.
Severe Outcomes The risk of Cardiac Arrhythmias, Renal Failure, and Metastatic Calcifications is documented in severe cases.

Official Emergency Actions Required

Regulatory documents mandate that users must seek immediate medical help right away if symptoms of toxicity or confirmed hypercalcemia develop. The product must be discontinued immediately. In severe cases, Hospital Monitoring is required.

Management focuses on supportive measures since no specific antidote is known for Cholecalciferol poisoning. Official procedures include aggressive Intravenous (IV) Hydration and the use of pharmacological agents such as Bisphosphonates to reduce serum calcium levels. This strategy defines the treatment protocol for the toxic state as described in authoritative prescribing information.

Advertisements

Therapeutic Uses of Calciprat Vitamine D3

What Calciprat Vitamine D3 Treats: Main Uses and Benefits

The core therapeutic domain for a combination product containing calcium carbonate and Vitamin D3 is the management and prevention of deficiencies in these essential nutrients, particularly in contexts that affect skeletal health. The product's indications generally involve the prevention and treatment of calcium and Vitamin D deficiency in adults. This combination is also commonly used as an adjunct to specific, established therapies for osteoporosis.

This is relevant in conditions characterized by periods of heightened symptoms where functional stability may be affected. When appropriate, this product is commonly used to help with symptoms related to physical discomfort and systemic imbalance. The general benefit is that it provides support that helps ease the overall symptom burden. Overall, it contributes to easing the overall symptom load and supports general well-being during symptomatic phases.


Quick Fact: May assist with Symptoms related to physical discomfort

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Calciprat Vitamine D3

Official regulatory documents strictly define the patient populations eligible to use Calciprat Vitamine D3 (Calcium Carbonate and Cholecalciferol). Use of this combined supplement is intended for adults and the elderly for the correction of established calcium and Vitamin D deficiencies.


Contraindicated Populations

The medicine is contraindicated and must not be used by patients with specific pre-existing conditions:

  • Hypercalcaemia (high blood calcium levels)
  • Hypercalciuria (high calcium excretion in urine)
  • Hypervitaminosis D (excessive Vitamin D levels)
  • Severe renal impairment (severe chronic kidney disease)
  • A history of Nephrolithiasis (kidney stones)

Population Limitations and Restrictions

Calciprat Vitamine D3 is not recommended for children and adolescents (individuals under 18 years of age).

Use during pregnancy and lactation is permitted only for the correction of an established deficiency; high-dose versions are generally not recommended due to the risk of fetal harm from maternal overdose. Conditional use requiring careful medical monitoring is mandated for patients with Sarcoidosis or those undergoing prolonged immobilisation.

Advertisements

What should I know about interactions with other medicines?

Calciprat Vitamine D3 Interactions with other medicines and products

Official regulatory information for Calciprat Vitamine D3 (Calcium Carbonate and Cholecalciferol) outlines specific interactions that impact drug absorption or affect calcium homeostasis. This section details these official constraints without providing individualized instructions or general safety information.


Timing Separation Requirements

Administration of Calciprat Vitamine D3 must be separated in time from several oral medicines, as the calcium carbonate component can reduce their absorption. Dose separation is required for products including Tetracycline and Quinolone antibiotics, Bisphosphonates, and Levothyroxine.

Pharmacodynamic and Metabolic Interactions

Interaction Type Interacting Agents Official Constraint Context
Calcium Homeostasis Risk Thiazide Diuretics Monitoring is required due to reduced urinary calcium excretion, which increases the risk of hypercalcaemia.
Cardiac Glycosides (e.g., Digitalis) Requires close monitoring, as hypercalcaemia can enhance toxicity.
Reduced Vitamin D Effect Phenytoin, Rifampicin Use with caution, as these medicines may decrease Vitamin D effectiveness through metabolic induction.
Impaired Absorption Bile Acid Sequestrants, Mineral Oils These products may reduce the absorption of the Cholecalciferol component.

Population-Specific Notes

The regulatory profile notes that the product is generally contraindicated in cases of severe renal insufficiency due to the body's inability to metabolize Cholecalciferol normally. This requires the use of other forms of Vitamin D if needed.

Advertisements

Mechanism of Action

VDR Agonism and Increased Intestinal Calcium Absorption

The Cholecalciferol (Vitamin D3) component is metabolized into Calcitriol, which acts as a powerful ligand for the nuclear Vitamin D Receptor (VDR) primarily in the small intestine. This VDR activation functions as a transcription factor, which upregulates the cellular capacity for calcium transport, including proteins like Calbindin and TRPV6. This mechanistic cascade increases the efficiency of Ca^2+ uptake from the gastrointestinal lumen into the bloodstream.

Substrate Provision and Endocrine Feedback

Simultaneously, the Calcium Carbonate component provides the essential Ca^2+ mineral substrate. This ionized calcium is utilized systemically, providing the necessary element for incorporation into the Hydroxyapatite crystalline structure of the bone matrix, which is required for skeletal matrix organization. The elevated systemic Ca^2+ concentrations initiate a negative feedback loop that results in the suppression of Parathyroid Hormone (PTH) release. By reducing the hormonal drive for bone resorption, the mechanism modulates the net balance of calcium flow within the homeostatic pathway.

Advertisements

Dosage and Administration Information

Administration Guidelines for Calciprat Vitamine D3

The instructions below detail the use and administration of Calciprat Vitamine D3 (Calcium Carbonate/Cholecalciferol).


Standard Use and Dosage

Instruction Detail
Route of Administration Oral route (Voie orale).
Dosage Form Chewable/suckable tablet (Comprimé à sucer).
Standard Adult Dose One tablet per day (once daily).
Intake Method The tablet must be chewed or sucked and then typically followed by a glass of water. It should not be swallowed whole.

Procedural Constraints

Specific administration rules are followed to ensure correct absorption and effectiveness:

  • Timing with Meals: The medicine can generally be taken with or without food.
  • Drug Separation Constraint: The tablet must be taken at least two to three hours apart from certain other medications, including tetracycline antibiotics, bisphosphonates, and sodium fluoride, to prevent interference with absorption.

Population-Specific Instructions

  • Paediatric Use: Use in children and adolescents is generally not intended for some strengths, such as the 1000 mg/800 IU formulation.
  • Use in Pregnancy: The maximum daily intake must not exceed 1,500 mg of calcium and 600 IU of vitamin D3. This often translates to half a tablet of the high-strength (1000 mg/800 IU) product.

This protocol describes the usage and timing requirements for this medication.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Clinical research has extensively evaluated the combined use of calcium (such as calcium carbonate) and Vitamin D3 (cholecalciferol) for bone health. This combination is generally utilized as a foundational element in both the prevention and treatment regimens for osteoporosis and conditions related to Vitamin D and calcium deficiency.


Efficacy in Fracture Reduction

Evidence from meta-analyses of randomized controlled trials (RCTs) suggests that supplementation with calcium and Vitamin D may be associated with a reduced risk of fractures in middle-aged and older adults, both those living in the community and those institutionalized. Specifically, studies have reported an observed reduction in the incidence of non-vertebral and hip fractures when compared to placebo.


Role in Bone Mineral Density (BMD)

Research has explored the effect of combination therapy on Bone Mineral Density (BMD), a measure of bone strength. Studies indicate that concurrent calcium and Vitamin D supplementation, as opposed to Vitamin D alone, may contribute to an increase in BMD. This effect is thought to be partly due to Vitamin D's role in enhancing the absorption of calcium from the intestine, which is essential for bone mineralization.


Clinical Context and Use

It is recognized that many individuals undergoing treatment for osteoporosis with prescription medications (such as bisphosphonates or other anti-resorptive agents) were also taking calcium and Vitamin D supplements during the clinical trials for those drugs. For this reason, supplemental calcium and Vitamin D are often administered alongside other therapies as a supportive measure. However, supplementation alone is generally not considered sufficient to eliminate fracture risk in all cases of established osteoporosis.

Key Studies & References Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Calciprat Vitamine D3 (FAQ)


Q: Is Calciprat Vitamine D3 the same as just taking a calcium supplement?

No, Calciprat Vitamine D3 is officially described as a combined mineral and vitamin supplement. It contains both calcium carbonate and cholecalciferol (Vitamin D3). The Vitamin D component is included because regulatory documents state that it significantly enhances the body's ability to absorb the calcium from the digestive system and use it effectively for bone health.


Q: Can Calciprat Vitamine D3 affect my sleep?

Official safety documents do not list common sleep disturbances as an expected side effect at standard doses. However, symptoms such as drowsiness or fatigue are officially associated with hypercalcemia (excessively high calcium levels), which is an uncommon side effect or a sign of an overdose. Any concerns regarding changes in sleep or other symptoms should be discussed with a healthcare provider.


Q: What happens if I forget to take a dose of Calciprat Vitamine D3?

According to typical patient information leaflets, if a dose is missed, official guidance often states that the missed dose may be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose is typically skipped. Official guidance emphasizes that taking a double dose to make up for a missed one is generally not advised.


Q: Does Calciprat Vitamine D3 interfere with iron supplements?

Yes, regulatory documents caution that the calcium salts in this product may reduce the absorption of iron supplements, which could potentially reduce the effectiveness of the iron. Official guidance for combined products often recommends separating the administration time from iron supplements by a specific time period, such as four hours, to help maintain absorption.


Q: What is the recommended duration of use for Calciprat Vitamine D3?

The required duration of use is not set as a fixed period but depends on the underlying deficiency or condition being addressed. For some uses, such as supporting osteoporosis treatment, the product may be intended for long-term use. Regulatory warnings indicate that the need for continued treatment requires regular medical reassessment and monitoring of calcium levels.


Q: Is Calciprat Vitamine D3 recommended for people with lactose intolerance?

Official product information for some formulations of Calciprat Vitamine D3 specifically lists lactose monohydrate as an inactive ingredient (excipient). Patients with known lactose intolerance typically check the ingredients list provided in the official patient leaflet for their specific formulation.


Q: Why might a doctor prescribe Calciprat Vitamine D3 instead of other supplements?

Regulatory documents indicate this product is prescribed when a patient requires correction of a combined deficiency of both calcium and Vitamin D, or as an adjunct therapy for osteoporosis where insufficient intake of both nutrients is contributing to bone loss. The dual formulation ensures the patient receives the necessary mineral substrate and the vitamin required to maximize its absorption.


Q: Does Calciprat Vitamine D3 contain any common allergens?

Regulatory documents are required to list all active and inactive ingredients (excipients). These lists may include specific warnings for known allergens (like trace elements of soya or lactose). It is generally advised that individuals consult the official patient information leaflet for their specific formulation to review all ingredients and check for known allergens.


Q: Does the product work better at a specific time of day?

No specific time of day is required for efficacy. Administration guidelines state that the chewable tablet can generally be taken at any time of day and with or without food. However, it is essential to follow the specific timing constraints for separating the dose from other medications.


Q: Can using Calciprat Vitamine D3 affect laboratory test results?

Yes, official guidance requires the regular monitoring of serum and urinary calcium levels because the product is designed to increase these levels, which will directly affect lab results. Furthermore, the calcium component can reduce the absorption of certain drugs, which might indirectly affect the results of monitoring for those specific medications.


Q: What if I experience an unexpected reaction after taking Calciprat Vitamine D3?

Patient leaflets typically recommend contacting a healthcare provider immediately if any unexpected reaction occurs, especially those not listed in the official safety profile. Reporting adverse events is an important process that helps national regulatory authorities monitor the medicine's safety.


Q: Is the dose of Vitamin D3 in this product considered high?

The standard dose in this product is set to correct or maintain sufficient Vitamin D levels for deficiency. Regulatory information defines a maximum daily intake (Tolerable Upper Intake Level), often around 4,000 IU/day for adults, which is used to prevent the risk of overdose. The prescribed dose is intended to stay within safe, therapeutic limits.


Q: What does official guidance say about stopping Calciprat Vitamine D3 use?

Official guidance indicates that if hypercalcaemia (excessively high calcium in the blood) or hypercalciuria (excessive calcium in the urine) occurs, the dose should be reduced or the treatment discontinued. Decisions regarding stopping treatment are typically determined by a healthcare provider after reassessing the patient’s condition and mineral levels.


Q: Is Calciprat Vitamine D3 suitable for individuals who are vegetarian or vegan?

The Cholecalciferol (Vitamin D3) component is often sourced from an animal origin, such as sheep's lanolin, or may be encapsulated in gelatin (also an animal source). The full composition list can be reviewed in the official patient leaflet for individuals concerned about vegetarian or vegan compliance.


Q: Is it described as a cure for any condition?

No. Regulatory documents describe this product as a supplement used to correct established deficiencies or as adjunct therapy for conditions like osteoporosis. It is not described in official therapeutic indications as a 'cure' for any condition.


Q: Why are people concerned about calcium supplements affecting heart health?

The official documentation requires close monitoring when this product is used alongside cardiac glycosides (heart medications like Digitalis). This is because high calcium levels (hypercalcaemia) can enhance the toxicity of these drugs, which carries a risk of serious side effects like arrhythmias (irregular heartbeats).


Q: Are there different forms of Calciprat Vitamine D3 available, like tablets or liquid?

Official information confirms that the product is available as a chewable or suckable tablet. While the regulatory documents for this specific product confirm the tablet form, other similar formulations containing these active ingredients may exist in national drug databases, potentially including liquid or solution forms.


Q: Is it true that Calciprat Vitamine D3 can cause kidney stones?

Regulatory documents list pre-existing Nephrolithiasis (kidney stones) as a contraindication, meaning people with stones should not use the drug. The drug can cause hypercalciuria (excess calcium in the urine) as an uncommon side effect, and prolonged high doses may lead to kidney calcification, which is a risk factor for stone formation.


Q: Are there specific foods that should be avoided when using this product?

Yes, official documents caution that foods containing high amounts of oxalic acid (found in spinach and rhubarb) or phytic acid (found in whole cereals) can inhibit calcium absorption. Official information generally advises separating the intake of the tablet from these foods by at least two hours to support proper absorption.


Q: Is it safe to take Calciprat Vitamine D3 with antacids?

Official interaction guidance often advises separation of administration times for drugs where calcium can interfere with absorption. While general antacids may not be specifically listed, products containing aluminum or magnesium are usually advised to be taken separately from calcium-containing supplements.


Q: Is Calciprat Vitamine D3 generally considered safe during pregnancy?

Use during pregnancy is permitted only for the correction of an established deficiency and requires medical supervision. Regulatory guidance sets strict maximum daily intake limits for both calcium and Vitamin D to ensure the total dose remains safe and to prevent the risk of fetal harm from maternal overdose.


Q: What are the signs of taking too much Calciprat Vitamine D3?

Signs of taking too much, leading to high calcium levels (hypercalcaemia), may include symptoms like nausea, vomiting, loss of appetite, excessive thirst, increased urination, headache, and weakness. Long-term overdosage is officially associated with the risk of kidney and tissue calcification.


Q: Is it normal to feel a bit bloated after starting Calciprat Vitamine D3?

Gastrointestinal disturbances are classified as Rare side effects in regulatory safety documents. The official terms include flatulence (gas), constipation, abdominal pain, and diarrhoea, which cover the symptoms commonly described by patients as 'bloating.'


Q: Can I take other vitamin supplements while on Calciprat Vitamine D3?

Official warnings advise that the dosage should account for the total intake of Vitamin D from all sources, including other vitamin supplements and fortified foods. This is to avoid Hypervitaminosis D (excessive Vitamin D), which is a contraindication. Monitoring total intake from all sources is an important part of managing therapy.


Q: What is the maximum daily amount of calcium and Vitamin D that is generally safe?

The maximum safe intake is generally defined by the point where the risk of toxicity, such as Hypercalcaemia, begins. Regulatory documents and health authorities often cite the Tolerable Upper Intake Level for Vitamin D as up to 4,000 IU/day for adults, which is used to prevent the risk of overdose.


Q: Why is it important to check existing Vitamin D levels before starting?

The dosage is determined based on existing requirements. Official guidance advises evaluating dietary habits and baseline levels before starting to ensure the total dose is appropriate. This step is important to prevent Hypervitaminosis D (excessive Vitamin D), which is a contraindication listed in the product's safety profile.


Q: Is Calciprat Vitamine D3 manufactured in different strengths?

Yes, official regulatory documents and national drug databases confirm that Calciprat Vitamine D3 is manufactured in multiple strengths. Examples include the 1000 mg calcium with 800 IU Vitamin D formulation, and often a lower strength such as 500 mg with 400 IU Vitamin D.

Advertisements

How should Calciprat Vitamine D3 be stored and disposed of?

Storage and Disposal of Calciprat Vitamine D3

Official labeling defines specific conditions necessary to maintain the integrity of Calciprat Vitamine D3 (Calcium Carbonate/Cholecalciferol) and ensure safety.


Required Storage Conditions

Storage Component Requirement
Temperature Store below 25 C. Do not refrigerate or freeze.
Protection Keep in the original package to protect from light and moisture.
Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Calciprat Vitamine D3 must not be thrown into household waste or wastewater. The disposal of the product must be conducted according to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calciprat Vitamine D3 found in:

A-Z Index: